Benitec Biopharma Ltd ADR BNTC

$8.98 -0.60 (-6.26%)

Valuation

Market cap
334,179,000
Revenue TTM
$0
Net income TTM
$-45,550,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
135,100
Avg volume
158,556
Day's range
$8.92 – $9.88
Shares out
34,883,000
Stochastic %K
2%
Beta
0.25
Analysts
Strong Sell
Price target
$24.33

Price

Company profile

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a s...

Show more

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene, which is in phase 1b/2a for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.

Industry
Biotechnology
Sector
Healthcare
Phone
510 780 0819
Website
https://benitec.com
Address
3940 Trust Way, Hayward, United States

Latest news

Stocktwits

focafoca99 Sep 24, 9:06 PM
$BNTC changed its independent auditor, dismissing Baker Tilly and appointing EY as the new audit firm.
0 replies
d_risk Sep 14, 8:32 PM
$BNTC - Benitec Biopharma Inc - 10K - Updated Risk Factors BNTC flags continued heavy losses, no product revenue, dependence on new capital to remain a going concern, early-stage unproven ddRNAi gene therapy facing tougher FDA demands and trial hurdles, heavy reliance on third parties and IP protection, uncertain physician/payer uptake, and added risks from U.S. government funding and FDA staffing disruptions. #Biopharmaceuticals #GeneTherapy #RegulatoryRisk #CapitalDependency #IntellectualProperty 🟢 Added 🟠 Removed https://d-risk.ai/BNTC/10-K/2026-09-14
0 replies
SuperGreenToday Jun 10, 8:31 PM
$BNTC Share Price: $10.40 Contract Selected: Oct 16, 2026 $10 Calls Buy Zone: $0.42 – $0.53 Target Zone: $0.71 – $0.87 Potential Upside: 57% ROI Time to Expiration: 127 Days | Updates via https://fxcapta.com/stockinfo/
0 replies
focafoca99 May 14, 12:32 PM
$BNTC released its fiscal quarter ended March 31, 2026 results and operational update.
0 replies
OpenOutcrier Apr 28, 12:34 PM
$BNTC (+2.2% pre) Benitec Biopharma to present BB-301 clinical data at gene therapy meeting https://ooc.bz/l/100204
0 replies
XCo Mar 24, 7:52 AM
$BNTC any other bitcoin big project stock?
0 replies
topstockalerts Mar 9, 4:06 PM
$BNTC Spec biotech that tends to react sharply to volume shifts. Recently showing stabilization after volatility. If it breaks resistance, fast momentum entries usually follow.
0 replies
OpenOutcrier Mar 9, 12:21 PM
$BNTC (+5.8% pre) Benitec reports positive interim results for OPMD gene therapy BB-301 https://ooc.bz/l/95947
0 replies